Circulating tumor DNA as a liquid biopsy for cancer.

BACKGROUND Targeted therapies have markedly changed the treatment of cancer over the past 10 years. However, almost all tumors acquire resistance to systemic treatment as a result of tumor heterogeneity, clonal evolution, and selection. Although genotyping is the most currently used method for categorizing tumors for clinical decisions, tumor tissues provide only a snapshot, or are often difficult to obtain. To overcome these issues, methods are needed for a rapid, cost-effective, and noninvasive identification of biomarkers at various time points during the course of disease. Because cell-free circulating tumor DNA (ctDNA) is a potential surrogate for the entire tumor genome, the use of ctDNA as a liquid biopsy may help to obtain the genetic follow-up data that are urgently needed. CONTENT This review includes recent studies exploring the diagnostic, prognostic, and predictive potential of ctDNA as a liquid biopsy in cancer. In addition, it covers biological and technical aspects, including recent advances in the analytical sensitivity and accuracy of DNA analysis as well as hurdles that have to be overcome before implementation into clinical routine. SUMMARY Although the analysis of ctDNA is a promising area, and despite all efforts to develop suitable tools for a comprehensive analysis of tumor genomes from plasma DNA, the liquid biopsy is not yet routinely used as a clinical application. Harmonization of preanalytical and analytical procedures is needed to provide clinical standards to validate the liquid biopsy as a clinical biomarker in well-designed and sufficiently powered multicenter studies.

[1]  Wen-Shyong Tzou,et al.  Molecular Detection of APC, K-ras, and p53 Mutations in the Serum of Colorectal Cancer Patients as Circulating Biomarkers , 2004, World Journal of Surgery.

[2]  K. Kinzler,et al.  Detection and quantification of rare mutations with massively parallel sequencing , 2011, Proceedings of the National Academy of Sciences.

[3]  H. Bonnefoi,et al.  Detecting tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  P. Laurent-Puig,et al.  Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients. , 2013, Clinical chemistry.

[5]  Anatoly Dritschilo,et al.  Multi‐marker analysis of circulating cell‐free DNA toward personalized medicine for colorectal cancer , 2014, Molecular oncology.

[6]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[7]  Valeri Vasioukhin,et al.  Point mutations of the N‐ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia , 1994, British journal of haematology.

[8]  B. Shapiro,et al.  Free DNA in the serum of cancer patients and the effect of therapy. , 1977, Cancer research.

[9]  K. C. Chan,et al.  Effects of preanalytical factors on the molecular size of cell-free DNA in blood. , 2005, Clinical chemistry.

[10]  M. Speicher,et al.  Establishment of tumor-specific copy number alterations from plasma DNA of patients with cancer , 2013, International journal of cancer.

[11]  U. Banerji,et al.  Multi-Purpose Utility of Circulating Plasma DNA Testing in Patients with Advanced Cancers , 2012, PloS one.

[12]  L. Mariani,et al.  Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. , 2001, Cancer research.

[13]  J. García-Verdugo,et al.  Molecular and Cellular Pathobiology Cancer Research Cell-Free Nucleic Acids Circulating in the Plasma of Colorectal Cancer Patients Induce the Oncogenic Transformation of Susceptible Cultured Cells , 2010 .

[14]  R. Schilsky,et al.  Implementing personalized cancer care , 2014, Nature Reviews Clinical Oncology.

[15]  M. Ychou,et al.  High Fragmentation Characterizes Tumour-Derived Circulating DNA , 2011, PloS one.

[16]  A. King,et al.  Early detection of nasopharyngeal carcinoma by plasma Epstein‐Barr virus DNA analysis in a surveillance program , 2013, Cancer.

[17]  M. Clemons,et al.  Discordance between receptor status in primary and metastatic breast cancer: an exploratory study of bone and bone marrow biopsies. , 2008, Clinical oncology (Royal College of Radiologists (Great Britain)).

[18]  A. Schneeweiss,et al.  Plasma DNA integrity as a biomarker for primary and metastatic breast cancer and potential marker for early diagnosis , 2014, Breast Cancer Research and Treatment.

[19]  Niels Pallisgaard,et al.  Quantitative Cell-Free DNA, KRAS, and BRAF Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan , 2012, Clinical Cancer Research.

[20]  Michael J Heller,et al.  Rapid electrokinetic isolation of cancer-related circulating cell-free DNA directly from blood. , 2014, Clinical chemistry.

[21]  Jesse J. Salk,et al.  Detection of ultra-rare mutations by next-generation sequencing , 2012, Proceedings of the National Academy of Sciences.

[22]  Frank Diehl,et al.  Detection and quantification of mutations in the plasma of patients with colorectal tumors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[23]  D. Swinkels,et al.  Effects of blood-processing protocols on cell-free DNA quantification in plasma. , 2003, Clinical chemistry.

[24]  Funda Meric-Bernstam,et al.  Overcoming implementation challenges of personalized cancer therapy , 2012, Nature Reviews Clinical Oncology.

[25]  I. Nagtegaal,et al.  KRAS gene amplification in colorectal cancer and impact on response to EGFR‐targeted therapy , 2013, International journal of cancer.

[26]  G. Baxter,et al.  Tumour seeding following percutaneous needle biopsy: the real story! , 2011, Clinical radiology.

[27]  G. Parmigiani,et al.  Detection of Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome Sequencing , 2012, Science Translational Medicine.

[28]  Katarzyna Sikora,et al.  Evaluation of cell-free DNA as a biomarker for pancreatic malignancies , 2015, The International journal of biological markers.

[29]  Peter Ulz,et al.  Circulating tumor cells and DNA as liquid biopsies , 2013, Genome Medicine.

[30]  Keitaro Matsuo,et al.  Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  U. Pastorino,et al.  Quantification of free circulating DNA as a diagnostic marker in lung cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Franck Molina,et al.  Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA , 2014, Nature Medicine.

[33]  Peter Ulz,et al.  Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing , 2013, Genome Medicine.

[34]  Carlos Caldas,et al.  Analysis of circulating tumor DNA to monitor metastatic breast cancer. , 2013, The New England journal of medicine.

[35]  I. Brandslund,et al.  Cell‐free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer , 2014, International journal of cancer.

[36]  R. Levine,et al.  Tumor Heterogeneity Confounds and Illuminates: Assessing the implications , 2014, Nature Medicine.

[37]  P Mandel,et al.  Les acides nucleiques du plasma sanguin chez l' homme , 1948 .

[38]  G. Sozzi,et al.  Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer. , 2008, Cancer letters.

[39]  Peiyong Jiang,et al.  Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing , 2013, Proceedings of the National Academy of Sciences.

[40]  Enzo Medico,et al.  Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer , 2012, Nature.

[41]  K. Pantel,et al.  Loss of Heterozygosity at Tumor Suppressor Genes Detectable on Fractionated Circulating Cell-Free Tumor DNA as Indicator of Breast Cancer Progression , 2012, Clinical Cancer Research.

[42]  F. O. Fackelmayer,et al.  DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. , 2001, Cancer research.

[43]  Karen Page,et al.  Genomic analysis of circulating cell-free DNA infers breast cancer dormancy. , 2012, Genome research.

[44]  T. Walsh,et al.  Microsatellite alterations plasma DNA of primary breast cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[45]  N. Rosenfeld,et al.  Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA , 2013, Nature.

[46]  K. Jung,et al.  Changes in concentration of DNA in serum and plasma during storage of blood samples. , 2003, Clinical chemistry.

[47]  Sanghee Kim,et al.  Circulating cell-free DNA as a promising biomarker in patients with gastric cancer: diagnostic validity and significant reduction of cfDNA after surgical resection , 2014, Annals of surgical treatment and research.

[48]  Alison S. Devonshire,et al.  Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification , 2014, Analytical and Bioanalytical Chemistry.

[49]  K. Kinzler,et al.  Digital PCR. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[50]  Bruno Landi,et al.  Detection of free‐circulating tumor‐associated DNA in plasma of colorectal cancer patients and its association with prognosis , 2002, International journal of cancer.

[51]  D. García-Olmo,et al.  Quantitation of cell-free DNA and RNA in plasma during tumor progression in rats , 2013, Molecular Cancer.

[52]  M. Stroun,et al.  Alu Repeat Sequences Are Present in Increased Proportions Compared to a Unique Gene in Plasma/Serum DNA , 2001, Annals of the New York Academy of Sciences.

[53]  Johannes G. Reiter,et al.  The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers , 2012, Nature.

[54]  Peiyong Jiang,et al.  Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. , 2013, Clinical chemistry.

[55]  P. Jiang,et al.  High-resolution profiling of fetal DNA clearance from maternal plasma by massively parallel sequencing. , 2013, Clinical chemistry.

[56]  Nicolai J. Birkbak,et al.  Computational optimisation of targeted DNA sequencing for cancer detection , 2013, Scientific Reports.

[57]  Peter Ulz,et al.  Changes in Colorectal Carcinoma Genomes under Anti-EGFR Therapy Identified by Whole-Genome Plasma DNA Sequencing , 2014, PLoS genetics.

[58]  M. Stroun,et al.  Neoplastic characteristics of the DNA found in the plasma of cancer patients. , 1989, Oncology.

[59]  Thomas Rösch,et al.  Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer , 2013, Gut.

[60]  B. Schäfer,et al.  Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia , 2008, Leukemia.

[61]  S. Leung,et al.  Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. , 2000, Cancer research.

[62]  M. Ychou,et al.  Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts , 2010, Nucleic acids research.

[63]  M. Stratton,et al.  Use of cancer‐specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors , 2010, Genes, chromosomes & cancer.

[64]  V. Servois,et al.  Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma , 2014, International journal of cancer.

[65]  Andrew M. K. Brown,et al.  Variable Clonal Repopulation Dynamics Influence Chemotherapy Response in Colorectal Cancer , 2013, Science.

[66]  Yama W. L. Zheng,et al.  Maternal Plasma DNA Sequencing Reveals the Genome-Wide Genetic and Mutational Profile of the Fetus , 2010, Science Translational Medicine.

[67]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[68]  S. Leung,et al.  Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[69]  S. Goodman,et al.  Circulating mutant DNA to assess tumor dynamics , 2008, Nature Medicine.

[70]  G. Hampton,et al.  Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib , 2011, Clinical Cancer Research.

[71]  Bert Vogelstein,et al.  DETECTION OF CIRCULATING TUMOR DNA IN EARLY AND LATE STAGE HUMAN MALIGNANCIES , 2014 .

[72]  H. Reber,et al.  Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. , 2006, Clinical chemistry.

[73]  Y. Lo,et al.  Rapid clearance of fetal DNA from maternal plasma. , 1999, American journal of human genetics.

[74]  Ash A. Alizadeh,et al.  An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage , 2013, Nature Medicine.

[75]  Jinn Shiun Chen,et al.  Comparison of KRAS mutation analysis of primary tumors and matched circulating cell-free DNA in plasmas of patients with colorectal cancer. , 2014, Clinica chimica acta; international journal of clinical chemistry.

[76]  N. Rosenfeld,et al.  Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA , 2012, Science Translational Medicine.

[77]  T. Kubiak,et al.  Direct Quantification of Cell-Free, Circulating DNA from Unpurified Plasma , 2014, PloS one.

[78]  Andrea Bertotti,et al.  Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. , 2013, Cancer discovery.

[79]  A. Jakobsen,et al.  Changes in mutational status during third‐line treatment for metastatic colorectal cancer—Results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma , 2014, International journal of cancer.